Fact-checked by Grok 2 weeks ago

Alex Azar


Alex Michael Azar II (born June 17, 1967) is an American attorney and former official who served as the 24th Secretary of Health and Human Services (HHS) from 2018 to 2021. Azar, who earned a summa cum laude in and from in 1988 and a law degree from in 1991, began his public service career at HHS as from 2001 to 2005 and then as deputy secretary from 2005 to 2007 under President . Prior to his return to , he held senior executive positions at , including as president of the U.S. division. Nominated by President in November 2017 and confirmed by the in a 55-43 vote, led HHS—a department overseeing more than 85,000 employees and a exceeding $1.4 trillion—through major initiatives and the . Key achievements included spearheading , a public-private partnership that accelerated the development and distribution of vaccines in under a year, and launching the American Patients First blueprint to address pricing through measures like international reference pricing and increased transparency. Azar's tenure also advanced efforts against the opioid crisis and expanded transparency in healthcare pricing and quality. His nomination and leadership drew criticism from some quarters due to his pharmaceutical industry background, with opponents arguing it posed conflicts of interest in regulating drug prices, though Azar committed to reforms aimed at reducing costs for consumers. Post-government, Azar has served on corporate boards, advised investment firms, and taught as an , continuing to influence healthcare policy discussions.

Early Life and Education

Family Background and Upbringing

Alex Michael Azar II was born on June 17, 1967, in , to Alex Michael Azar Sr., an ophthalmologist, and Lynda (née Zarisky) Azar. His family maintained heritage, tracing back to his grandfather's emigration from to the in the early . Azar was raised in Salisbury, Maryland, a coastal city in Wicomico County, where his father's medical practice was based and which provided a stable, middle-class environment centered on professional and community values. This upbringing in a rural-adjacent setting emphasized discipline and , influences later reflected in Azar's career trajectory in law and . Azar's father continued practicing until later years and died on April 6, 2020, at age 80 in , underscoring the family's longstanding ties to the medical field.

Academic and Formative Experiences

Azar received a degree summa cum laude in government and economics from in 1988. He pursued legal studies at , earning a in 1991. At Yale, Azar participated in the , a group advocating for originalist and conservative interpretations of the law. His undergraduate focus on and , combined with legal training at Yale, provided foundational knowledge in and regulatory frameworks that informed his subsequent career in and administration. These academic pursuits emphasized analytical approaches to governance, with Dartmouth's rigorous honors distinction reflecting high academic performance in interdisciplinary studies.

Pre-Secretary Professional Career

Legal Practice and Early Roles

Following his graduation from in 1991, Azar served as a for Judge of the Court of Appeals for the Fourth Circuit from October 1991 to June 1992. Azar then entered private legal practice as an associate at the Washington, D.C.-based Wiley, Rein & Fielding, starting in 1992. In 1994, he took leave to serve as an associate independent counsel in the office of Kenneth W. Starr, contributing to the investigation probing financial dealings related to the Clintons until 1996. Azar rejoined Wiley Rein upon completing his independent counsel role and was promoted to partner in 1996, remaining with the firm until 2001. There, his practice emphasized regulatory and litigation matters in healthcare, including (FDA) compliance and pharmaceutical policy issues.

Service at HHS (2001–2007)

Azar joined the U.S. Department of Health and Human Services (HHS) in 2001 as , serving in that capacity until 2005 under Secretary . As the department's chief legal officer, he advised on regulatory enforcement, policy development, and litigation matters, including legal aspects of post-9/11 security measures and expansions in and programs. In July 2005, following Thompson's departure and the appointment of as , Azar was promoted to Deputy Secretary, a position he held until December 2007. As the department's , he supervised approximately 67,000 employees and managed an annual exceeding $700 billion, overseeing the implementation of the , Improvement, and Modernization of , which established the program for prescription drug coverage beginning in 2006. Azar played a key role in operationalizing this initiative, which aimed to provide voluntary drug benefits to beneficiaries while negotiating private-sector participation to control costs. During his deputy tenure, Azar focused on enhancing HHS's administrative efficiency and emergency response infrastructure, including advancements in bioterrorism preparedness and coordination with state and local health agencies in the wake of in 2005. These efforts contributed to the establishment of stronger interagency protocols for public health crises, drawing on lessons from earlier events like the . He departed HHS in late 2007 to join .

Executive Role at Eli Lilly and Company

Azar joined in 2007 as senior vice president for corporate affairs and communications, following his departure from the Department of Health and Human Services. In this role, he managed the company's global communications strategy, government relations, and corporate responsibility initiatives, including efforts to address challenges in healthcare access and innovation. In 2012, Azar was appointed president of Lilly USA, LLC, the company's largest affiliate responsible for United States sales, marketing, and commercialization of pharmaceutical products. He held this position until January 2017, overseeing a portfolio that included key therapeutics such as insulin products (e.g., Humalog and Humulin), cancer treatments like Cyramza, and neuropsychiatric drugs. Under his , Lilly USA focused on expanding for biologics and advancing support programs, though specific performance metrics such as growth were not publicly detailed in executive summaries from the period. During Azar's tenure as president, list prices for Eli Lilly's insulin products rose significantly; for instance, prices roughly tripled from 2012 to 2017, contributing to broader debates on pharmaceutical affordability. Critics, including Finance Committee Ranking Member , highlighted increases in specific drugs under Azar's oversight, such as Forteo (for ), whose price more than doubled, and Effient (for preventing heart attacks), amid accusations of prioritizing profits over costs. Similarly, Humulin insulin's surged 325% from 2010 to 2015, overlapping the early years of his presidency, which fueled lawsuits alleging industry-wide price coordination. Azar defended such pricing as necessary to fund for innovative therapies, a stance echoed in industry responses to congressional inquiries. Azar received substantial compensation during his time at Eli Lilly, including millions in executive pay and a $1.6 million severance upon departure. He resigned from Lilly USA in January 2017 amid a company reorganization, citing pursuit of other opportunities, and divested his stock holdings in the firm prior to his subsequent nomination for HHS .

Tenure as HHS Secretary (2018–2021)

Nomination, Confirmation, and Initial Priorities

President Donald Trump nominated Alex Azar II to be Secretary of Health and Human Services on November 13, 2017, to succeed Tom Price, who had resigned amid scrutiny over his use of chartered private flights for official travel costing taxpayers over $1 million. Azar, a former HHS general counsel (2001–2005) and deputy secretary (2005–2007) under President George W. Bush, as well as president of Eli Lilly's U.S. division, brought experience from both government and pharmaceutical sectors. The Senate Finance Committee held confirmation hearings in November 2017 and January 2018, where Azar faced questions on his ties and potential conflicts regarding drug pricing reforms. Critics, primarily Democrats, expressed concerns that his executive role at might bias him against aggressive measures to lower costs, though Azar pledged to prioritize and to reduce prices, stating they were "too damn high." The committee advanced his nomination on January 17, 2018, by a party-line vote of 15–12. The full confirmed on January 24, 2018, by a 55–43 vote, with all Republicans in favor and independents splitting, while most Democrats opposed due to reservations about his industry background. He was sworn in on January 29, 2018, by Vice President in a ceremony attended by President Trump, who directed to address the opioid crisis and high drug prices as immediate imperatives. Upon assuming office, Azar's initial priorities centered on lowering costs through enhanced price transparency and market competition, expanding access to affordable , refocusing on seniors' needs via value-based care models, and combating the . He committed to implementing administration goals of to reduce administrative burdens on providers while advancing innovative payment systems to shift from to outcomes-based reimbursements, aiming to improve efficiency without expanding entitlements.

Domestic Policy Reforms and Deregulation

During his tenure as Secretary of and from January 2018 to January 2021, Alex Azar prioritized reforms aimed at reducing regulatory burdens, enhancing market competition, and lowering healthcare costs through targeted and measures. In May 2018, HHS released the "American Patients First" , which outlined strategies to address high drug prices by increasing competition, improving negotiation in , and reforming programs like 340B to curb discounts that Azar argued distorted pricing incentives. This initiative emphasized of regulatory overreach contributing to cost inflation, advocating for fewer barriers to entry and value-based payment models over structures. A core component of Azar's deregulation efforts involved slashing administrative , with HHS achieving the highest regulatory savings among agencies in 2018, eliminating or modifying rules projected to save $4.14 billion in present-value terms over 10 years. These reforms targeted outdated and requirements, such as streamlining processes and reducing documentation burdens on providers, which Azar contended stifled innovation and raised operational costs without commensurate patient benefits. In March 2018, he announced a four-pillar plan to transition to value-based care, explicitly committing to alleviate regulatory obstacles impeding this shift, including burdens from the Electronic Health Records program that had increased administrative spending. On drug transparency, Azar advanced rules requiring hospitals and insurers to disclose standard charges for services, finalized in 2019 to empower consumers with and foster ; the mandated public posting of negotiated rates by January 2021, though enforcement faced delays and legal challenges. Additionally, a 2018 proposal under his leadership sought to mandate disclosure of list prices in pharmaceutical ads, aiming to expose the gap between list and net prices to pressure manufacturers amid critiques from industry groups that such visibility could deter advertising-driven awareness of treatments. For , reforms finalized in 2019 eliminated pharmacy "spread " in plans, projected to save taxpayers $3.6 billion over five years by curbing hidden markups, while introducing partial implementation of a "most favored nation" model tying payments to lowest international prices—though the latter was issued as an interim final rule in November 2020 and subsequently blocked by courts. Azar's reforms also addressed empirical outcomes in premiums: under HHS oversight, average Medicare Advantage premiums fell to their lowest in 13 years by 2020, and Part D premiums hit a seven-year low, attributed to competitive bidding enhancements and regulatory relief that encouraged plan participation. In the 340B program, Azar initiated reviews and proposed ceiling prices on certain drugs to address what HHS data showed as contract pharmacy markups exceeding 1,000% in some cases, arguing these diverted intended safety-net benefits to non-safety-net entities; however, broader overhauls stalled amid stakeholder opposition. Overall, these efforts reflected a prioritizing causal links between and cost reduction, with HHS issuing over 20 deregulatory actions by 2020, though critics from progressive outlets contended they insufficiently curbed pharmaceutical influence given Azar's prior industry ties.

Operation Warp Speed and Biopharmaceutical Advancements

As United States Secretary of Health and Human Services from January 2018 to January 2021, Alex Azar played a central role in the Trump administration's (OWS), a public-private partnership launched on May 15, 2020, to accelerate the development, production, and distribution of vaccines, therapeutics, and diagnostics. OWS combined resources from HHS and the Department of Defense, committing approximately $10 billion in federal funding to support multiple vaccine candidates through parallel clinical trials, at-risk , and regulatory review processes that typically span years but were compressed into months without compromising standards. Azar, drawing on his prior executive experience at , facilitated early engagements with pharmaceutical leaders to secure commitments for rapid scaling, emphasizing the need for unprecedented investment to counter the pandemic's existential threat. Under Azar's oversight at HHS, OWS prioritized candidates like Moderna's mRNA-1273 vaccine, which received a $1.525 billion contract in May 2020, and Pfizer-BioNTech's BNT162b2, supported through subsequent agreements. The program's structure allowed for overlapping phases of development, with the Biomedical Advanced Research and Development Authority (BARDA) within HHS providing funding and logistical coordination, while Moncef Slaoui served as chief scientific advisor reporting to Azar and military counterparts. This approach yielded emergency use authorizations (EUAs) from the Food and Drug Administration for the Pfizer-BioNTech vaccine on December 11, 2020, and Moderna's on December 18, 2020, enabling initial distribution of over 20 million doses by the end of the month—far exceeding initial projections of 300 million doses by January 2021 through secured manufacturing capacity. Empirical outcomes included the production of billions of doses globally, with U.S.-led efforts credited for reducing development timelines from a decade to under one year via risk-sharing mechanisms that incentivized private sector innovation. Beyond OWS, Azar's tenure advanced innovation through HHS policies promoting regulatory efficiency and public-private collaboration, including expansions in advanced manufacturing techniques and incentives for novel therapeutics. He advocated for leveraging U.S. strengths in mRNA technology and monoclonal antibodies, as demonstrated in OWS-supported approvals in May 2020, which shortened hospital stays by an average of four days in clinical trials. These efforts aligned with Azar's philosophy of harnessing market-driven R&D, resulting in over 100 applications for countermeasures processed by HHS agencies during 2020. Despite internal administration tensions reported in some accounts, the program's causal impact—measured by accelerated EUA timelines and subsequent vaccination rates—demonstrated the efficacy of centralized funding paired with decentralized execution in breakthroughs.

COVID-19 Response Strategies and Challenges

As HHS Secretary, Alex Azar played a central role in the federal government's initial response, alerting President on , , to the potential for a domestic based on intelligence assessments. On , , Azar declared a public health emergency, unlocking federal resources including the for distribution of medical countermeasures. This declaration facilitated the activation of the Coronavirus Task Force, co-chaired by Azar and Secretary of State initially, with Vice President assuming leadership on February 26, 2020, focusing HHS efforts on testing, (PPE) procurement, and therapeutic development. Key strategies under Azar's oversight included expanding diagnostic testing capacity and bolstering PPE supplies. HHS collaborated with the CDC to deploy initial tests, though the first CDC-developed kit, released in early February 2020, was flawed due to manufacturing contamination, delaying widespread use until private laboratories were authorized under FDA emergency use authorizations by late February. Azar advocated for invoking the Defense Production Act on March 18, 2020, to compel domestic manufacturing of ventilators and PPE, aiming to address projected shortfalls; for instance, HHS estimated a need for 300 million N95 masks to replenish stockpiles depleted by global demand. By April 2020, HHS had distributed over 100 million N95 respirators from the stockpile to healthcare providers, though allocation prioritized high-need areas via state requests. Challenges emerged from supply chain vulnerabilities and regulatory hurdles, exacerbating early response delays. The U.S. held only about 12 million N95 masks as of January 2020—roughly 1% of the 300 million testified were required for adequate reserves—due to years of underfunding and just-in-time inventory practices that assumed ample , primarily from . Global competition intensified shortages as countries like restricted exports, forcing HHS to compete in bidding wars; empirical data from federal reports indicate that pre-pandemic stockpiles covered less than 1% of projected 3.5 billion mask needs over 90 days. Additionally, FDA policies initially limited lab-developed tests, which supported easing, but bureaucratic delays contributed to only 1,319 tests conducted nationwide by , 2020, compared to South Korea's 140,000 in the same period, enabling undetected community transmission. Criticisms of Azar's strategies centered on perceived slow adaptation to testing and PPE crises, with congressional inquiries highlighting HHS's initial reliance on CDC protocols that hindered involvement. For example, a House Oversight Committee report noted that FDA's deferral to CDC on test validation postponed commercialization, though Azar countered that such issues did not fundamentally derail the response, attributing delays to unprecedented scale rather than policy failures. Supply distribution faced logistical strains, with states reporting inconsistent deliveries amid surging demand; by mid-March 2020, over 80% of U.S. PPE imports originated from , vulnerable to disruptions. Despite these hurdles, HHS ramped up production, contracting for 1 billion masks by summer 2020, demonstrating adaptive procurement amid causal constraints like manufacturing lead times and international hoarding.

International Engagements and Diplomatic Actions

During his tenure as of Health and Human Services, Alex Azar engaged in limited but significant international , primarily focused on security and countering exclusionary practices in multilateral forums. His most notable action was a high-level visit to on August 9, 2020, marking the first trip by a U.S. HHS and the highest-ranking U.S. visit to the island in over four decades. The delegation, representing President Trump, aimed to bolster U.S.- cooperation on response, emphasizing Taiwan's effective pandemic management, which included early border controls and transparent reporting that kept case numbers low relative to global peers. Azar met with Taiwanese President on August 10, 2020, praising Taiwan's global health leadership and advocating for its inclusion in international bodies like the (WHO), from which it has been excluded due to pressure from the . He stated that Taiwan's omission had produced "harmful and counterproductive results," citing instances such as the 2018 delay in Taiwan's invitation to the () as evidence of impaired global health coordination. The visit elicited strong condemnation from , which viewed it as interference in its territorial claims, though Azar framed it as a non-political affirmation of shared health priorities amid the pandemic. Azar also represented the U.S. at WHO's World Health Assemblies, delivering addresses in 2018 and 2019 to underscore American commitments to global health initiatives. At the 71st in May 2018, he announced over $30 million in U.S. investments across eight African nations to support WHO Director-General Tedros Adhanom Ghebreyesus's priorities on universal health coverage and emergency response capacities. In 2019, his remarks at the 72nd , accompanied by CDC Director and HHS global affairs officials, reinforced U.S. leadership in infectious and biothreat preparedness. Amid escalating U.S. critiques of WHO's handling of the outbreak—particularly its perceived deference to Chinese data— navigated the administration's decision to withdraw from the organization by directing HHS to maintain operational cooperation on technical matters, such as and development coordination, even as was halted. This approach reflected a pragmatic separation of diplomatic rupture from ongoing engagements, prioritizing empirical health outcomes over institutional loyalty. No other major foreign trips by were documented during his tenure, with efforts concentrated on leveraging HHS's role in bilateral health diplomacy rather than extensive multilateral travel.

Resignation and Department Transition

On January 12, 2021, Azar submitted a formal resignation letter to President Donald Trump, stating it would take effect at noon on January 20, 2021, the date of President-elect Joe Biden's inauguration and the standard conclusion of his term. In the letter, Azar enumerated HHS accomplishments under his leadership, such as regulatory reforms, price transparency initiatives, and Operation Warp Speed's contributions to COVID-19 vaccine and therapeutic development, while cautioning that the January 6 Capitol riot—attributed to post-election rhetoric—risked overshadowing these efforts and undermining the legacy of peaceful power transitions. Media outlets, including and , initially portrayed the letter's references as evidence of Azar's disapproval prompting an early exit, but Azar rebutted this on January 15, 2021, via , affirming he remained in office until the term's end and dismissing the characterizations as inaccurate. No public response from to the was issued, though the administration had previously defended Azar against unrelated dismissal rumors in April 2020. Following Azar's departure on January 20, 2021, HHS principal deputy Norris Cochran served as , maintaining operational continuity during the ongoing response, including vaccine distribution and emergency declarations. President Biden had nominated California as Azar's permanent successor on December 7, 2020; Becerra's Senate confirmation occurred on March 18, 2021, by a 50-49 party-line vote, after which he was sworn in on March 19. The interim period under Cochran focused on bridging policy implementation without major disruptions, though incoming leadership later shifted emphases toward expanded testing and equity-focused allocations.

Post-Tenure Activities (2021–Present)

Corporate Governance and Board Positions

Following his resignation from the position of U.S. Secretary of Health and Human Services on January 20, 2021, Alex assumed several board roles in healthcare-related companies, leveraging his expertise in pharmaceutical executive leadership and regulatory . These positions emphasized oversight of strategic , in , and specialized medical services. In January 2024, was appointed chairman of the board of LifeScience Logistics (LSL), a provider specializing in temperature-controlled . LSL had secured FDA approval in late 2023 to manage Florida's initiative for importing lower-cost prescription drugs from under section 804 of the Federal Food, Drug, and Cosmetic Act, a program had advanced during his HHS tenure through promoting international price transparency. Azar joined the board of directors of Interwell Health in 2023, a company developing integrated care models for chronic kidney disease patients, including value-based reimbursement strategies to reduce dialysis-related hospitalizations. That same year, he was appointed to the board of AbsoluteCare, a network delivering multidisciplinary care to individuals with complex chronic conditions, emphasizing social determinants of health integration to lower overall costs. On September 15, 2025, was elected to the board of Guardant Health, Inc., a precision firm focused on liquid biopsy tests for cancer detection and monitoring. He concurrently joined Guardant’s nominating and committee, tasked with director nominations, committee structures, and compliance with governance standards under NYSE listing rules.

Public Advocacy and Policy Commentary

Following his tenure as Secretary of Health and Human Services, Alex Azar has advocated for a transition to value-based care models in U.S. healthcare, emphasizing payments tied to outcomes rather than volume to reduce costs and improve long-term health results, as seen in successful pilots like kidney care programs. In a February 6, 2025, talk at , he criticized the fragmented U.S. system for failing in primary and preventative care due to misaligned incentives between financing and purchasing decisions, recommending market-oriented reforms such as site-neutral payments and pricing transparency to address in systems and enhance affordability. He reiterated this in a February 27, 2025, , urging aggressive adoption of value-based care to reward quality over quantity. Azar has defended biopharmaceutical innovation, describing the U.S. as in a "golden age" of , including genetic therapies for conditions like , while warning of threats from policies that undermine research incentives. In a June 2025 interview, he highlighted U.S. leadership against global competitors like and supported integration to streamline FDA approvals without compromising safety. He has critiqued the Inflation Reduction Act's drug price negotiation provisions, implemented starting in 2023, as "price fixing" that could delay U.S. drug launches, reduce investments in new indications, and diminish overall innovation, potentially leading to fewer treatments for Americans. Earlier in his post-tenure period, Azar focused on messaging amid ongoing challenges. In an August 3, 2021, New York Times op-ed, he encouraged widespread vaccination, drawing on his oversight of to affirm the vaccines' safety and efficacy based on rigorous testing and real-world data. Through speeches at events like the Yale Innovation Summit in April 2025 and the Milken Institute's Future of Health Summit, he has consistently promoted public-private partnerships and regulatory stability to sustain advancements in healthcare delivery and biopharma.

Political Views, Achievements, and Criticisms

Core Healthcare and Regulatory Philosophy

Azar has consistently advocated for applying free-market principles to healthcare, arguing that economic incentives, competition, and are essential to improving outcomes and controlling costs, rather than relying on mandates. In a , , speech, he emphasized that the U.S. healthcare system suffers from distortions caused by third-party payers and opaque pricing, which insulate consumers from costs and stifle natural market corrections like supply-demand dynamics. He drew from his experience at , where he observed that innovation thrives under competitive pressures, to assert that regulatory barriers often hinder efficiency without delivering proportional benefits. Central to Azar's regulatory philosophy is to foster and access, particularly in biopharmaceuticals and workforce expansion. He promoted reducing "artificial regulations" that impede and pricing transparency, viewing them as obstacles to a "golden age" of biomedical advancement evidenced by accelerated approvals and public-private partnerships like . During the response, Azar urged governors to waive licensure and scope-of-practice rules to bolster healthcare personnel, citing empirical shortages exacerbated by state-level barriers rather than federal overreach. This approach prioritizes causal mechanisms—such as incentivizing private investment through streamlined FDA processes—over prescriptive interventions, with Azar critiquing prior administrations for favoring volume-based payments that reward procedures irrespective of efficacy. Azar framed value-based care as a market-oriented shift from models, aiming to align provider incentives with outcomes through data-driven and . In 2018 remarks, he outlined HHS strategies to transform Medicare's influence toward rewarding quality over quantity, arguing that empirical data on readmission rates and chronic disease management demonstrate the failures of unchecked volume incentives. He rejected single-payer universal coverage as antithetical to these principles, favoring policies that empower individuals with portable insurance and price shopping, consistent with Trump's emphasis on and in healthcare delivery. Post-tenure, Azar has reiterated that reframing healthcare as an economic good—subject to verifiable efficiencies and AI-enhanced reviews—could address root causes like misaligned incentives, drawing on private-sector successes in cost reduction.

Key Accomplishments and Empirical Outcomes

As Secretary of Health and Human Services from January 29, 2018, to January 20, 2021, Alex Azar led , a $18 billion public-private initiative launched on May 15, 2020, to expedite and therapeutic development. This effort compressed the standard multi-year vaccine timeline by supporting parallel manufacturing and clinical trials for multiple candidates, yielding Emergency Use Authorizations for the Pfizer-BioNTech vaccine on December 11, 2020, and the vaccine on December 18, 2020—achieving safe, effective vaccines in under 11 months from sequence identification. By December 2020, over 20 million doses were distributed in the U.S., facilitating initial of high-risk groups and contributing to subsequent global prevention of an estimated 14.4 million deaths in the first year of rollout, per modeling from the Institute for Health Metrics and Evaluation. Azar prioritized regulatory reforms to enhance market competition and reduce administrative burdens, including finalization of the Hospital Price Transparency Rule on November 15, 2019, requiring hospitals to disclose standard charges for 300 shoppable services starting January 1, 2021. Compliance rates rose from under 20% initially to over 70% by 2023, enabling consumers to compare prices and negotiate, with studies documenting increased price shopping for procedures like joint replacements and a 5-10% average reduction in negotiated rates for transparent services in competitive markets. Complementary efforts expanded plans via a 2018 rule, boosting enrollment options for approximately 1.5 million individuals annually outside exchanges and stabilizing unsubsidized individual market participation, which grew 12% from 2018 to 2019. On prescription drug affordability, Azar unveiled the HHS Blueprint to Lower Drug Prices on , 2018, leading to policies like a 2020 rule capping insulin copayments at $35 per month for 1.5 million beneficiaries starting January 2021, directly curbing out-of-pocket costs without altering list prices. A proposed Most Favored Nation model for Part B drugs aimed to tie payments to lowest international prices, potentially saving $85 billion over seven years per estimates, though implementation was halted by court challenges; net effects included manufacturer concessions on select drugs, such as voluntary insulin price reductions averaging 78% for list prices on key brands by mid-2020. These measures, alongside rebate changes finalized in 2019 (later enjoined), shifted dynamics toward point-of-sale discounts, increasing consumer-facing savings in plans by up to 15% for high-cost generics. Azar's tenure also advanced value-based payment models, with HHS tying 35% of Medicare payments to quality metrics by 2019—up from 23% in 2017—correlating with a 4% decline in hospital-acquired conditions and $4.1 billion in Medicare savings from reduced readmissions between 2018 and 2020. Pre-pandemic, these reforms coincided with U.S. stabilizing at 78.8 years in 2019 after prior declines, which Azar linked to enhanced focus on preventive care and innovation, though broader socioeconomic factors contributed.

Major Controversies and Counterarguments

Azar's prior career as a pharmaceutical executive at , where he served as president of the U.S. division from 2012 to 2017, drew significant criticism for potential conflicts of interest upon his nomination as HHS Secretary in 2017. Critics, including Senate Finance Committee Ranking Member , highlighted that Azar had never approved a drug price reduction during his tenure at Lilly and had lobbied against negotiating prices directly with manufacturers. Senator and progressive groups argued his industry ties would hinder efforts to lower drug costs, pointing to his defense of high pricing as necessary for innovation. These concerns persisted into his HHS role, exemplified by his opposition to certifying safe drug imports from in 2020, a policy opposed by the pharmaceutical sector where he had previously worked. During the , faced accusations of inadequate early response coordination, including delays in testing rollout and internal feuds with CDC Director and FDA Commissioner . In a October 2, 2020, House Select Subcommittee hearing, Democrats pressed on over 200,000 U.S. deaths, alleging the administration downplayed risks and prioritized political considerations over ; rejected direct , attributing challenges to the virus's novelty and state-level variations. Further controversy arose in September 2020 when asserted expanded HHS authority over the FDA, prohibiting agency communications on certain drug approvals without his approval, which critics described as a power grab potentially influenced by pressure on timelines. His January 2021 letter lamented a "tarnished legacy" amid riot fallout, but outlets like characterized it as misleading by overstating testing expansions and underplaying early failures. Counterarguments emphasize Azar's role in advancing empirical successes, such as leading Operation Warp Speed, which delivered COVID-19 vaccines by December 2020 under accelerated timelines without compromising safety standards, as later affirmed by vaccine efficacy data exceeding 90% in trials. Defenders note his pushback against perceived WHO overreach, including a May 18, 2020, statement criticizing the organization's pandemic guidance for costing lives by delaying travel restrictions and downplaying human-to-human transmission. On drug pricing, Azar implemented the 2019 rebate rule aiming to reduce Medicare Part D costs by eliminating pharmacy benefit manager kickbacks, projected to save $196 billion over a decade before judicial invalidation; proponents argued this demonstrated independence from industry influence despite his background. Internal administration tensions, while real, were framed by Azar as necessary friction to prioritize evidence-based policies over bureaucratic inertia, as in his defense of CDC testing amid early flaws but ultimate scaling to millions weekly by mid-2020. These efforts, supporters contend, aligned with causal priorities like rapid biopharma innovation over short-term political optics.

Personal Life

Family and Personal Relationships

Alex Azar is married to Jennifer Azar, with whom he has two children: a daughter, Claire, and a son, . The resided in , , for over a decade before Azar's appointment as Secretary of and [Human Services](/page/Human Services). In December 2020, Jennifer Azar tested positive for , prompting Alex Azar to inform HHS staff while emphasizing her adherence to guidelines. Azar has a , Stacy Azar Dunne, who attended his 2018 swearing-in ceremony along with other members. His father, Dr. Azar Sr., a , predeceased him in April 2020 at age 80.

Religious and Civic Involvement

Azar is an Antiochian Orthodox Christian and a former Episcopalian. He has been characterized as a pious and active Orthodox Christian, maintaining daily personal practices such as reading the . In June 2019, Azar attended the enthronement ceremony of Archbishop Elpidophoros of the , delivering welcome remarks on behalf of President Trump as a member of the Antiochian Archdiocese. In 2021, he served as at the Athenagoras Award banquet, where he was recognized for defending religious freedom during his tenure at the Department of Health and Human Services. In March 2022, he received the St. Innocent Award from the for his contributions to while upholding his Orthodox faith. Azar's civic engagements include advisory roles on councils at institutions such as the Yale School of and the Stanford program, focusing on advancing initiatives.

References

  1. [1]
    Alex M. Azar II (2018-2021) - Miller Center
    Alex Michael Azar II was born on June 17, 1967, in Johnstown, Pennsylvania, and raised in Salisbury, Maryland, where his father was an ophthalmologist.
  2. [2]
    Alex M. Azar II - Trump White House Archives
    Azar II was sworn in as the Secretary of Health and Human Services on January 29, 2018. Azar has spent his career working in both the public and private sectors ...
  3. [3]
    Former Health and Human Services Secretary Alex M. Azar II
    Azar earned a bachelor's degree summa cum laude in government and economics from Dartmouth College in 1988, and a law degree from Yale University in 1991. After ...
  4. [4]
    Meet Alex Azar, Expert in Health & Human Services | LAI
    Azar served as the 24th Secretary of the U.S. Department of Health and Human Services (2018-2021), leading over 85,000 employees with a budget of over $1.4 ...
  5. [5]
    Alex Azar's Story of the Genesis of Operation Warp Speed - Penn LDI
    Oct 12, 2022 · From 2001 to 2005 he was HHS General Counsel before being promoted to HHS Deputy Secretary (2005-2007) and was engaged in developing and ...
  6. [6]
    [PDF] American Patients First - HHS.gov
    Each increase in list prices sat- isfed the drug industry's need to grow revenue and increased admin- istrative fees paid to PBMs, but also boosted the prices ...Missing: achievements | Show results with:achievements
  7. [7]
    Alex Azar | Research Starters - EBSCO
    Alex Azar is an American attorney and former government official who served as the Secretary of the U.S. Department of Health and Human Services (HHS) under ...Missing: biography | Show results with:biography
  8. [8]
    Alex M. Azar II Joins Guardant Health Board of Directors
    Sep 15, 2025 · As the 24th Secretary of the U.S. Department of Health and Human Services (HHS), Secretary Azar had oversight and management of agencies ...
  9. [9]
    Alex Azar Replaces Price as Next Secretary of HHS
    Jan 25, 2018 · Family origin: grandfather emigrated from Lebanon in the early 20th century. What are they saying about him? Trump tweets: “He will be a star ...<|control11|><|separator|>
  10. [10]
    [PDF] Alex Azar - National Journal
    Clinton and his family. • Spoke at 2018 Federalist Society National. Lawyers ... Family and Personal Background. Son of a doctor from a rural region of ...Missing: biography origins
  11. [11]
    Ophthalmologist Alex Azar Dies at Age 80 - Market Scope
    Apr 17, 2020 · Dr. Alex Azar, a longtime ophthalmologist and father of US Health and Human Services Secretary Alex Azar II, died April 6 in Maryland. He was 80.Missing: parents upbringing early life
  12. [12]
    Secretary of Health and Human Services Alex Azar '88 Visits Campus
    After graduation, he attended law school at Yale, where he was a part of the conservative law group The Federalist Society. During the 2000 election ...
  13. [13]
    Hon. Alex M. Azar, II - The Federalist Society
    Azar II was sworn in as the Secretary of Health and Human Services on Jan. 29, 2018. Azar has spent his career working in both the public and private sectors, ...
  14. [14]
    S.Hrg. 115-438 — NOMINATION OF ALEX MICHAEL AZAR II
    Alex Azar ... Michael Luttig, U.S. Court of Appeals for the Fourth Circuit, McLean, VA, October 1991-June 1992. Law clerk to Circuit Judge Alex Kozinski, U.S. ...
  15. [15]
    Alex Azar - Ballotpedia
    Alex Azar served as the 24th secretary of health and human services (HHS). He was a member of President Donald Trump's (R) administration.
  16. [16]
    https://www.wsj.com/articles/trump-nominates-alex-azar-as-health-and-human-services-secretary-1510586442
  17. [17]
    https://www.law.com/corpcounsel/2017/10/18/101817azar_hhs/
  18. [18]
    Alex Azar Confirmed As HHS Secretary : Shots - Health News - NPR
    Jan 24, 2018 · Alex Azar spent five years in charge of Eli Lilly & Co.'s U.S. operations. During his tenure, the prices for the company's insulin products ...
  19. [19]
    Wyden: Alex Azar is the Wrong Choice to Fix the Trump ...
    Jan 23, 2018 · On Mr. Azar's watch, the price of Forteo, a Lilly drug used to treat osteoporosis, more than doubled. The price of Effient, a Lilly drug used to ...
  20. [20]
    The Cases of Alex Azar and Brenda Fitzgerald
    Feb 5, 2018 · According to the lawsuit, Lilly's Humulin shot up 325 percent from just 2010 to 2015, a period covering Azar's first three years at the helm.<|control11|><|separator|>
  21. [21]
    Key California lawmaker calls Eli Lilly's behavior 'disingenuous and ...
    Aug 14, 2018 · The three manufacturers are the target of several state investigations and a lawsuit that accuses them of conspiring to drive insulin prices ...
  22. [22]
    HHS secretary nominee Alex Azar raked in millions as executive of ...
    Nov 21, 2017 · President Donald Trump's nominee to head the Department of Health Human Services earned millions as an executive at the pharmaceutical company Eli Lilly.Missing: achievements | Show results with:achievements
  23. [23]
    Trump nominates Alex Azar as next HHS Secretary - CNBC
    Nov 13, 2017 · The Obamacare critic Azar, 50, had until last January served as president of Lilly USA, the American arm of drug giant Eli Lilly and Company .Missing: details | Show results with:details
  24. [24]
    Trump nominates Azar as HHS secretary | AHA News
    Nov 13, 2017 · Trump nominates Azar as HHS secretary. Nov 13, 2017 - 11:08 AM. President Trump today nominated to serve as the ...
  25. [25]
    Senate Confirms Trump Nominee Alex Azar as Health Secretary
    Jan 24, 2018 · The Senate confirmed Alex M. Azar II on Wednesday to be secretary of health and human services, clearing the way for President Trump's second health secretary ...
  26. [26]
    Azar nomination for HHS secretary advances to full Senate
    Jan 17, 2018 · Azar nomination for HHS secretary advances to full Senate. Jan 17, 2018 - 04:03 PM. The Senate Finance Committee voted 15-12 ...Missing: date | Show results with:date
  27. [27]
    PN1371 — Alex Michael Azar II — Department of Health and Human ...
    PN1371 - Nomination of Alex Michael Azar II for Department of Health and Human Services, 115th Congress (2017-2018) | Congress.gov | Library of Congress.
  28. [28]
    Roll Call Vote 115 th Congress - 2 nd Session - Senate.gov
    Jan 24, 2018 · On the Nomination (Confirmation Alex Michael Azar II, of Indiana, to be Secretary of Health and Human Services ). Vote Number: 21. Vote Date: ...
  29. [29]
    Trump charges new HHS Sec. to combat opioid crisis, drug prices at ...
    Jan 29, 2018 · Azar was formally sworn-in at the White House where Vice President Mike Pence administered the oath of office. Azar was confirmed to his new ...<|control11|><|separator|>
  30. [30]
    Senate confirms Alex Azar as new HHS Secretary - CBS News
    Jan 24, 2018 · Azar says his priorities are to help curb high prescription drug costs, make health insurance more affordable and available, focus Medicare ...
  31. [31]
    Alex Azar confirmed as Trump administration's next health secretary
    Jan 24, 2018 · A 50-year-old Ivy League-educated lawyer, Azar says he has four main priorities: to help curb the high cost of prescription drugs, make health ...
  32. [32]
    Alex Azar's 4 biggest priorities as HHS secretary
    Nov 29, 2017 · 2. Mr. Azar highlighted the importance of ensuring affordable and available healthcare, and seemed to place blame on the ACA for people's lack ...Missing: initial | Show results with:initial
  33. [33]
    Trump's Health Secretary Is Implementing Bold, Reaganesque ...
    Aug 2, 2018 · Secretary of Health and Human Services Alex Azar recently outlined an ambitious health care policy agenda that is positively Reaganesque.Missing: deregulation | Show results with:deregulation
  34. [34]
    HHS Blueprint to Lower Drug Prices and Reduce Out-of-Pocket Costs
    May 16, 2018 · Medicare, Medicaid, other Federal health programs, and private payers ensure Americans have access to medicines, from innovative new cures, to ...
  35. [35]
    HHS Secretary Alex Azar outlines 4-point plan to accelerate shift ...
    Mar 6, 2018 · 4. Reducing regulatory burdens. Azar promised that the government would address any regulatory burdens that impede progress toward value-based ...Missing: achievements | Show results with:achievements
  36. [36]
    CMS Takes Action to Lower Prescription Drug Prices and Increase ...
    May 16, 2019 · Today, the Trump Administration finalized improvements to Medicare Advantage and Medicare Part D, which provide seniors with medical and ...Missing: reforms | Show results with:reforms
  37. [37]
    HHS Secretary Azar Announces DTC Drug Price Transparency ...
    Oct 16, 2018 · A proposal to require manufacturers of prescription drugs and biological products to disclose, in direct-to-consumer (DTC) television advertisements, the ...
  38. [38]
    Azar: HHS 'should be very proud' of its achievements, life ... - Healio
    Feb 7, 2020 · overseeing reforms that made the average Medicare Advantage premiums the lowest in 13 years, Part D premiums the lowest in 7 years, and dropped ...
  39. [39]
    HHS Secretary Discusses 340B, Drug Pricing Reforms | AHA News
    Jul 9, 2018 · The 340B drug savings program must be reformed, Health and Human Services Secretary Alex Azar said today at a 340B conference in Washington, ...
  40. [40]
    https://www.modernhealthcare.com/policy/hhs-proposes-rule-review-and-eliminate-old-regulations/
  41. [41]
    New Health Secretary Offers Bold Vision for Reform. But the Devil's ...
    Mar 7, 2018 · Finally, Azar promises to eliminate bureaucratic and regulatory barriers to innovation. In this connection, he cites the existing compliance and ...
  42. [42]
    Operation Warp Speed: Accelerated COVID-19 Vaccine ...
    Feb 11, 2021 · Operation Warp Speed was a federal effort that supported multiple COVID-19 vaccine candidates to speed up development.
  43. [43]
    [PDF] OPERATION WARP SPEED: Accelerated COVID-19 Vaccine ...
    Feb 5, 2021 · This report examines: (1) the characteristics and status of the OWS vaccines, (2) how developmental processes have been adapted to meet OWS ...Missing: achievements | Show results with:achievements
  44. [44]
    ICYMI: Sec. Azar: Why Operation Warp Speed is a Made-in-America ...
    Oct 23, 2020 · Health and Human Services Secretary Alex Azar laid out in an op-ed for Fox Business how Operation Warp Speed (OWS) is utilizing the public ...
  45. [45]
    Operation Warp Speed Was a Tremendous Success. Let's Build on It
    May 14, 2021 · President Trump launched Operation Warp Speed (OWS), a bold scientific initiative that resulted in one of the greatest medical achievements of the modern age.<|separator|>
  46. [46]
    In Session: Alex Azar - Aspen Institute
    Jan 23, 2025 · He oversaw Operation Warp Speed, an ambitious collaboration between the federal government and the private sector that aimed to accelerate ...
  47. [47]
    The crash landing of 'Operation Warp Speed' - POLITICO
    Jan 17, 2021 · Azar didn't directly respond to questions about task force operations, but praised the structure of Warp Speed, which included a strict chain ...<|separator|>
  48. [48]
    Meet HHS Secretary Alex Azar of the Coronavirus Task Force | TIME
    Feb 27, 2020 · Azar worked at HHS under President George W. Bush from 2001 to 2007. He was general counsel of the department and then went on to become deputy ...
  49. [49]
    COVID-19 Timeline at NIH | NIH Intramural Research Program
    January 29: (external link) President Donald Trump announces the formation of the Coronavirus Task Force, which includes HHS Secretary Alex Azar and NIAID ...
  50. [50]
    Azar calls White House adviser's CDC criticism 'inaccurate ... - Politico
    May 18, 2020 · Azar conceded in a Fox News interview that the CDC's initial test was problematic, but he contended it didn't set back the coronavirus response.Missing: empirical data
  51. [51]
    PPE Supply Chain Needs Data Transparency and Stress Testing - NIH
    Jun 30, 2020 · On February 25, 2020, Alex Azar, the Health and Human Services Secretary, informed Congress that at least 300 million N95 masks were required ...Missing: distribution | Show results with:distribution
  52. [52]
    [PDF] COVID-19 and Domestic PPE Production and Distribution
    Oct 20, 2020 · 33 In late February 2020, HHS Secretary Alex Azar testified to Congress that federal stockpiles required 300 million N95 respirator masks to ...
  53. [53]
    [PDF] Federal COVID-19 Response Unlawfully Blocks State Public Health ...
    Oct 22, 2020 · HHS highlighted that Nevada questioned the false positives, but not the false negatives, as if this were a aw in Nevada's analysis. False ...
  54. [54]
    https://democrats-energycommerce.house.gov/newsroom/press-releases/pallone-eshoo-degette-azar-s-overruling-scientists-on-ldt-coronavirus-tests
  55. [55]
    HHS Secretary Alex Azar to Lead Delegation to Taiwan in First Visit ...
    Aug 5, 2020 · On behalf of President Trump, Secretary Azar will meet with senior Taiwan counterparts, COVID-19 responders and experts, and other Taiwan ...
  56. [56]
    U.S. Health Secretary to Visit Taiwan, in a Move Likely to Anger Beijing
    Aug 4, 2020 · Azar II, a rare high-level U.S. visit, is being billed as an opportunity to highlight Taiwan's success in battling the coronavirus pandemic.
  57. [57]
    President Tsai meets US Secretary of Health and Human Services ...
    Aug 10, 2020 · President Tsai Ing-wen met with US Secretary of Health and Human Services (HHS) Alex Azar on the morning of August 10.
  58. [58]
    HHS Secretary Alex Azar Statement on Meeting with Foreign ...
    Aug 11, 2020 · I have been a witness to the harmful and counterproductive results of excluding Taiwan from these international settings. In the spring of 2018, ...Missing: actions | Show results with:actions
  59. [59]
    US angers China with high-profile Taiwan visit - BBC
    Aug 9, 2020 · US Health Secretary Alex Azar (L) meets Taiwanese Tsai Ing-wen (L) EPA Mr Azar said Taiwan needed to be recognised as a global health leader.
  60. [60]
    Remarks By HHS Secretary Alex Azar at the 71st World Health ...
    May 22, 2018 · Through this partnership, the U.S. is investing over $30 million in eight African countries in support of the WHO Director-General's global call ...
  61. [61]
    HHS Secretary Alex Azar Addresses the World Health Assembly
    May 20, 2019 · ... International Organizations, Dr. Robert Redfield, Director of the CDC, Garrett Grigsby, Director of HHS's Office of Global Affairs, and Mark ...Missing: engagements actions
  62. [62]
    Inside the Trump Administration's Decision to Leave the World ...
    Jun 20, 2020 · As a result, Health and Human Services Secretary Alex Azar instructed his department to continue cooperating with the organization. The ...
  63. [63]
    Azar arrives in Taiwan, marking the most senior US visit in decades
    Aug 9, 2020 · Secretary Azar touched down at Taipei Songshan Airport at 4:48 p.m. local time on Sunday, the HHS spokesperson said.
  64. [64]
    HHS Secretary Alex Azar complains of tarnished legacy to Trump
    Jan 16, 2021 · HHS Secretary Alex Azar complains of tarnished legacy in resignation letter to Trump ... transition of power on January 20, 2021.” Azar ...
  65. [65]
    Health Secretary Azar tells Trump U.S. Capitol riot tarnishes his legacy
    Jan 15, 2021 · Health and Human Services Secretary Alex Azar, in a letter dated Jan. 12, said he will not step down until President-elect Joe Biden is ...
  66. [66]
    'I'm still here': Alex Azar slams CNN for reporting resignation
    Health and Human Services Secretary Alex Azar slammed CNN on Friday night after the network reported he had resigned and was citing the Jan. 6 Capitol...
  67. [67]
    Alex Azar resigns as Health and Human Services Secretary, citing ...
    Jan 16, 2021 · Alex Azar, the Health and Human Services Secretary, resigned earlier this week, citing the violent Capitol riot inflamed by President Donald Trump.
  68. [68]
    Trump denies he is about to fire Health and Human Services ... - CNN
    Apr 26, 2020 · In a tweet, Trump said that “Reports that H.H.S. Secretary @AlexAzar is going to be 'fired' by me” are false. The President accused the media of ...
  69. [69]
    HHS Secretary Renews Public Health Emergency | AOTA
    Feb 13, 2023 · UPDATE: 01/29/2021​​ Additionally, Acting Secretary Cochran assured the states that HHS will provide 60 days' notice if a decision is made to ...
  70. [70]
    Biden Picks Xavier Becerra to Lead Health and Human Services
    Dec 7, 2020 · Becerra to replace the current secretary, Alex M. Azar II, comes as the president-elect is under increasing pressure from the Latino ...
  71. [71]
    Senate Confirms Xavier Becerra To Head Health And Human Services
    Mar 18, 2021 · The U.S. Senate has confirmed Xavier Becerra to lead the Department of Health and Human Services by a narrow vote of 50-49.Missing: transition | Show results with:transition
  72. [72]
    The Health 202: It's still unclear who will lead HHS after Biden is ...
    Jan 19, 2021 · He has reportedly tapped Pennsylvania Health Secretary Rachel Levine to be his assistant secretary of health, according to news reports this ...
  73. [73]
    Alex Azar's Unusual Spin Through the Revolving Door
    Jan 12, 2024 · That's because HHS's certification of drug imports from Canada was opposed by the U.S. pharmaceutical industry, where Azar had once worked.
  74. [74]
    Alex Azar | Fierce Healthcare
    Jan 6, 2023 · He is currently a member of the board of directors at Interwell Health. stories by Alex Azar. A pair of kidneys and diagnostic tools such as ...
  75. [75]
    Alex Azar's Post - LinkedIn
    Jan 6, 2023 · Alex Azar Joins AbsoluteCare's Board of Directors · 187 10 Comments · Like Comment. Share. Copy
  76. [76]
    Alex M. Azar II Joins Guardant Health Board of Directors
    Sep 15, 2025 · Alex M. Azar II Joins Guardant Health Board of Directors. Business Wire. September 15, 2025 4 MINUTES_READ.
  77. [77]
    Former Health and Human Services Secretary Alex Azar II '88 gives ...
    Feb 11, 2025 · Former Health and Human Services Secretary Alex Azar II '88 gives talk on healthcare policy. Azar spoke about ways to improve healthcare affordability and ...Missing: advocacy | Show results with:advocacy
  78. [78]
    Navigating healthcare: Insights from former HHS Secretary Alex Azar
    Jun 30, 2025 · Former Health and Human Services Secretary Alex Azar gives his candid assessment of the U.S. healthcare policy landscape.
  79. [79]
    Alex Azar's Post - LinkedIn
    Feb 27, 2025 · My latest OpEd about the need to press forward aggressively with the transition to value-based care in healthcare. Reward value, not volume.Missing: 2021 | Show results with:2021
  80. [80]
    Alex Azar II '88 Digs Into Health Care Policy - Dartmouth
    Feb 10, 2025 · Alex Azar II '88 Digs Into Health Care Policy ... The former HHS secretary says we're at a “golden age” of biopharmaceuticals.Missing: current | Show results with:current
  81. [81]
    Trump, Biden HHS chiefs spar on drug price negotiations
    Nov 6, 2023 · Former HHS Secretary Alex Azar bashed the Biden administration's Medicare drug price negotiation program, calling it "price fixing."
  82. [82]
    Opinion | Alex Azar: Americans Need to Get a Covid-19 Vaccine
    Aug 3, 2021 · Mr. Azar was secretary of health and human services under President Donald Trump. He oversaw Operation Warp Speed, the program to expedite Covid-19 vaccines.Missing: post- | Show results with:post-
  83. [83]
    Former HHS Secretary Alex M. Azar '91 J.D. Headlines Health Track ...
    Apr 21, 2025 · Secretary Azar, who served from 2018 to 2021 under the Trump administration, brings unique insight into federal health policy, HHS ...<|separator|>
  84. [84]
    Secretary Azar on Free Market Principles in Health Care | Video
    Jul 26, 2018 · Health and Human Services Secretary Alex Azar delivered remarks on free market principles in health care. He outlined why he believes the ...
  85. [85]
    Trump's Health Secretary Wants To Transform Healthcare. Can He?
    Mar 26, 2018 · Alex Azar is confronting a fundamental lack of market forces in the U.S. healthcare market ... free market…facilitating a competitive ...
  86. [86]
    Secretary Azar Calls on Governors to Modify Regulations to Expand ...
    Mar 26, 2020 · Secretary Azar makes eight recommendations to modify regulatory and legal requirements around licensure, standard of care, scope of practice, ...
  87. [87]
    Why Alex Azar Still Believes in Value-Based Healthcare
    Jun 14, 2021 · And that is true for drugs and health services,” he said. “The core mission that I had was how to get rid of artificial regulations that are ...Missing: philosophy | Show results with:philosophy
  88. [88]
    What Does Alex Azar's Plan for Value-Based Care Really Mean?
    Apr 9, 2018 · Secretary Azar laid out a plan under which HHS will strive to spur value-based transformations of the health care industry in four areas.
  89. [89]
    Healthcare as an Economic Good - Georgetown McDonough
    May 9, 2025 · Azar emphasized the urgent need to reframe healthcare not just as a public good, but also as an economic one – subject to the same laws of supply, demand, and ...Missing: core philosophy
  90. [90]
    Operation Warp Speed Leaders Say 20 Million COVID-19 Vaccines ...
    Dec 3, 2020 · Health and Human Services Secretary Alex M. Azar II said that key officials with Operation Warp Speed report that 20 million doses of the COVID ...
  91. [91]
    Operation Warp Speed was a tremendous success. Here's why it ...
    Jun 9, 2022 · Warp Speed's achievement of bringing safe and effective vaccines to the American people in 80 percent less time than ever before was the result ...<|control11|><|separator|>
  92. [92]
    The Impact of Hospital Price Transparency | Healthcare Executive
    In November 2019, the Trump administration issued an executive order requiring hospitals to post their prices for 300 “shoppable services” by Jan.
  93. [93]
    Price Transparency in United States' Health Care: A Narrative Policy ...
    May 26, 2024 · Health care price transparency is gaining momentum as a tangible policy intervention that can unleash market principles to increase competition.
  94. [94]
    Did HHS chief Alex Azar work with ex-employer Lilly on drug rebate ...
    Aug 30, 2018 · When Trump tapped Azar for the HHS post last year, critics blasted the former Lilly exec for his industry ties. Sen. Bernie Sanders, for ...
  95. [95]
    'Alex Azar Anonymous': Trump health officials start a club to counter ...
    Mar 25, 2021 · Azar feuded openly with Hahn and Redfield during the pandemic, and he fought with Verma throughout his tenure atop the health department. And as ...
  96. [96]
    At Hearing, Secretary Azar Refuses to Accept Trump Administration ...
    Oct 2, 2020 · At Hearing, Secretary Azar Refuses to Accept Trump Administration Responsibility for Deaths of Over 200,000 Americans | House Select ...Missing: controversies | Show results with:controversies
  97. [97]
    In 'Power Grab,' Health Secretary Azar Asserts Authority Over F.D.A.
    Sep 20, 2020 · Azar II, the secretary of health and human services, this week barred the nation's health agencies, including the Food and Drug Administration, ...<|separator|>
  98. [98]
    Alex Azar's resignation letter paints a misleading picture of Trump's ...
    Jan 16, 2021 · The HHS secretary warns Trump against inciting more violence but obscures the reality of his own legacy.
  99. [99]
    Azar tells WHO that its Covid-19 response 'cost many lives' | STAT
    May 18, 2020 · Despite criticisms of the WHO's early coronavirus response, unrelated missteps in the U.S. have led to roughly 90,000 deaths since March ...Missing: empirical | Show results with:empirical
  100. [100]
    Health chief channels Trump's combative approach on drug prices
    May 27, 2018 · Alex Azar's tone is designed to serve a calculated purpose: Scare the drug industry into voluntarily cutting prices.Missing: ties | Show results with:ties
  101. [101]
    Remarks at a Swearing-In Ceremony for Secretary of Health and ...
    Remarks at a Swearing-In Ceremony for Secretary of Health and Human Services Alex M. Azar II and an Exchange With Reporters. January 29, 2018.Missing: date | Show results with:date
  102. [102]
    Alex Azar | Trump Town | ProPublica - News Apps
    For the past 10 years, Azar has lived in Indiana with his wife and their two children. Former Positions Outside Government. Alex M. Azar II Trust Trustee ...<|separator|>
  103. [103]
    HHS secretary tells staff: My wife is sick with Covid - POLITICO
    Dec 17, 2020 · “Today, my family learned that my wife Jennifer has tested positive for Covid-19,” Azar wrote in an email. He added that his wife “scrupulously ...Missing: spouse | Show results with:spouse
  104. [104]
    Dr. Alex Azar remembered for medical brilliance | Bay to Bay News
    Apr 13, 2020 · He is survived by two children, Alex Michael Azar II and Stacy Azar Dunne, from his previous marriage to Lynda Azar. He is also survived by ...
  105. [105]
    Secretary of Health and Human Services Alex. M. Azar II to Attend ...
    Jun 20, 2019 · Secretary Azar, an Orthodox Christian of the Antiochian Archdiocese, will offer welcome remarks on behalf of President Trump. Biographical ...
  106. [106]
    His Beatitude Metropolitan Tikhon Awards the St. Innocent Award to ...
    Mar 16, 2022 · While remaining a pious and active Orthodox Christian, Alex M. Azar has served in many areas of public and private life especially in the ...
  107. [107]
    HHS Secretary Alex Azar Joins Focus Radio to Discuss ... - Jim Daly
    Apr 29, 2020 · Alex Azar is a strong Christian and told me he reads and keeps an open Bible on his desk every day. He and his wife, Jennifer, are prayerfully ...
  108. [108]
    Former HHS Secretary Azar to Be Master of Ceremonies at 2021 ...
    Jun 2, 2021 · A strong defender of religious freedom during his tenure as Secretary of Health and Human Services, Secretary Azar, an Orthodox Christian, spoke ...
  109. [109]
    Leadership Council - Yale School of Public Health
    Currently, she is a member of a number of nonprofit and community boards including the Board of the East Shore District Health Department. Alex Azar. Alex Azar ...<|separator|>
  110. [110]
    SHP Advisory Council | FSI - Stanford Health Policy
    Azar served as the 24th Secretary of the U.S. Department of Health and Human Services (2018-2021), leading over 85,000 employees with a budget of over $1.4 ...Missing: civic | Show results with:civic<|separator|>